Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

402 results about "Mood disorders" patented technology

Affective disorders are a set of psychiatric diseases, also called mood disorders. The main types of affective disorders are depression, bipolar disorder, and anxiety disorder. Symptoms vary by individual, and can range from mild to severe.

Method of treating depression, mood disorders and anxiety disorders using neuromodulation

The present invention involves a method and a system for using electrical stimulation and / or chemical stimulation to treat depression. More particularly, the method comprises surgically implanting an electrical stimulation lead and / or catheter that is in communication with a predetermined site which is coupled to a signal generator and / or infusion pump that release either an electrical signal and / or a pharmaceutical resulting in stimulation of the predetermined site thereby treating the mood and / or anxiety.
Owner:ADVANCED NEUROMODULATION SYST INC

Selective neurostimulation for treating mood disorders

ActiveUS20070027500A1Relieve symptomsAlter modulation of neuronal activityHead electrodesDiseaseRegimen
A method and device for treating a mood and / or anxiety disorder are disclosed which comprise electrical, chemical or magnetic stimulation of certain areas of the brain to modulate neuronal activity of areas associated with symptoms of mood disorders. In certain embodiments, deep brain stimulation is combined with cranial nerve stimulation to enhance symptomatic relief of the disorder. Certain embodiments also employ a sensing capability to optimize the therapeutic treatment regimen.
Owner:LIVANOVA USA INC

Diagnostic markers of mood disorders and methods of use thereof

InactiveUS20050176057A1Negative predictive accuracyMaximizing sensitivityBiocideBiostatisticsAssayProper treatment
The present invention relates to methods for the diagnosis, evaluation, and treatment of mood disorders, particularly bipolar disorder. In particular, patient test samples are analyzed for the presence and amount of members of a panel of biallelic markers comprising one or more specific markers for bipolar treatment and one or more non-specific markers for bipolar treatment. A variety of markers are disclosed for assembling a panel of markers for such diagnosis and evaluation. Algorithms for determining proper treatment are disclosed. A diagnostic kit for a panel of said markers is disclosed. In various aspects, the invention provides methods for the early detection and differentiation of mood disorders or bipolar treatment. Methods for screening therapeutic compounds for mood disorders are disclosed. The invention (1) gives methods providing rapid, sensitive and specific assays that can greatly increase the number of patients that can receive beneficial treatment and therapy, thereby reducing the costs associated with incorrect diagnosis, and (2) provides methods for improved therapies.
Owner:BREMER TROY +1

Method of treating mood disorders and/or anxiety disorders by brain stimulation

The present invention involves a method and a system for using electrical stimulation and / or chemical stimulation to treat depression. More particularly, the method comprises surgically implanting an electrical stimulation lead and / or catheter that is in communication with a predetermined site which is coupled to a signal generator and / or infusion pump that release either an electrical signal and / or a pharmaceutical resulting in stimulation of the predetermined site thereby treating the mood and / or anxiety disorder.
Owner:ADVANCED NEUROMODULATION SYST INC

Method of treating depression, mood disorders and anxiety disorders using neuromodulation

The present invention involves a method and a system for using electrical stimulation and / or chemical stimulation to treat depression. More particularly, the method comprises surgically implanting an electrical stimulation lead and / or catheter that is in communication with a predetermined site which is coupled to a signal generator and / or infusion pump that release either an electrical signal and / or a pharmaceutical resulting in stimulation of the predetermined site thereby treating the mood and / or anxiety.
Owner:ADVANCED NEUROMODULATION SYST INC

Method and apparatus for diagnosis of a mood disorder or predisposition therefor

InactiveUS6629935B1Great absolute magnitude of changeEasy to changeIndividual molecule manipulationSensorsDiseaseBinocular rivalry
A method for diagnosis of a mood disorder or predisposition therefor in a test subject is disclosed. The method includes the steps of determining an interhemispheric switch rate of the test subject, and comparing the switch rate with a corresponding reference switch rate to diagnose presence or absence of the mood disorder or predisposition therefor. In a preferred embodiment, the interhemispheric switch rate is determined by measuring the rate of binocular rivalry in the test subject. Also disclosed is an apparatus for diagnosis of a mood disorder or predisposition therefor, use of the diagnostic method in genetic linkage studies for the identification of the molecular defect(s) underlying these disorders, and for the identification of compounds which may alleviate such disorders.
Owner:QUEENSLAND UNIV OF THE

Multistage safety screening of equipment operators

Methods and systems to screen equipment operators for impairments, such as intoxication, physical impairment, medical impairment, or emotional impairment, to selectively test the equipment operators and control the equipment if impairment of the equipment operator is determined. One embodiment is a method to screen an equipment operator for intoxication. A second embodiment is a method to screen an equipment operator for impairment, such as intoxication, physical impairment, medical impairment, or emotional impairment. A third embodiment is an equipment operator screening system to determine impairment, such as intoxication, physical impairment, medical impairment, or emotional impairment.
Owner:VEHICLE INTELLIGENCE & SAFETY

Electrochromic device and photodynamic treatment device comprising such an electrochromic device

InactiveUS20100082081A1Increase the light areaOptimize and tune transmissionLight therapyNon-linear opticsAbnormal tissue growthBladder Infections
Presently, many variations of light treatment are used in health care. Prime examples are the in-vivo or ex-vivo photodynamic treatment (PDT) of skin diseases, cancer / tumors, psoriasis, mood disorders, bladder infections, promoting wound closure, recovering spinal cord injuries, and countering muscle / bone atrophy. PDT is a treatment that uses a drug, called a photo-sensitizer or photosensitizing agent, and a particular type of light. The invention relates to an improved PDT device.
Owner:KONINKLIJKE PHILIPS ELECTRONICS NV

Method of treating depression, mood disorders and anxiety disorders using neuromodulation

The present invention involves a method and a system for using electrical stimulation and / or chemical stimulation to treat an affective disorder, such as depression. More particularly, the method comprises surgically implanting an electrical stimulation lead and / or catheter that is in communication with a predetermined site which is coupled to a signal generator and / or infusion pump that release either an electrical signal and / or a pharmaceutical resulting in stimulation of the predetermined site thereby treating the mood and / or anxiety.
Owner:ADVANCED NEUROMODULATION SYST INC

Systems and Methods for Analyzing and Assessing Depression and Other Mood Disorders Using Electroencephalographic (EEG) Measurements

This invention is directed to systems and methods for analyzing depression, and more particularly relates to systems and methods for analyzing and assessing depression and mood disorders in an individual using electroencephalographic measurements. Embodiments of the invention are not limited to depression, but can also include other mood disorders such as bipolar disorder and other disorders with at least one genetic-related component.
Owner:NEBA HEALTH

Portable light delivery apparatus and methods

A portable light delivery device for delivering light to the blood supply of a human body through a nonocular area of skin on the body includes an attachment member, a portable light delivery unit connected to the attachment member and a portable power supply. The portable light delivery unit provides one or more wavelengths of light within a specifically determined range of intensity and a specifically determined angle of illumination. A portable control unit may be included on the light delivery device for selectively controlling the light delivery unit. A programming device associated with the control unit selectively changes the programming of the controller. The light delivery device is portably secured to a region of the body having a substantial amount of blood vessels near the surface thereof to deliver light to the blood supply of the body for treating mood disorders, seasonal affective disorder and disorders involving circadian rhythm and sleep.
Owner:PHILIPS ELECTRONICS NORTH AMERICA

Neurostimulation device for treating mood disorders

A device and method for treating a mood and / or anxiety disorder are disclosed which provide for stimulation of certain areas of the brain to modulate neuronal activity of areas associated with symptoms of mood disorders. In certain embodiments, brain stimulation is combined with cranial nerve stimulation for enhancing symptomatic relief of the disorder. Certain embodiments also employ a sensing capability for optimizing the therapeutic treatment regimen.
Owner:LIVANOVA USA INC

Delta9 tetrahydrocannabinol (Delta9 THC) solution metered dose inhalers and methods of use

InactiveUS20020031480A1BiocideNervous disorderAnorecticMuscles spasticity
The present invention provides therapeutic formulations for solutions of DELTA9-tetrahydrocannabinol (DELTA9 THC) to be delivered by metered dose inhalers. The formulations, which use non-CFC propellants, provide a stable aerosol-deliverable source of DELTA9 THC for the treatment of various medical conditions, such as: nausea and vomiting associated with chemotherapy-muscle spasticity; pain; anorexia associated with AIDS wasting syndrome, epilepsy; glaucoma; bronchial asthma; and mood disorders.
Owner:VIRGINIA COMMONWEALTH UNIV

DELTA9 Tetrahydrocannabinol (DELTA9 THC) solution metered dose inhaler

InactiveUS6509005B1BiocideNervous disorderPharmacologyMuscles spasticity
The present invention provides therapeutic formulations for solutions of DELTA9-tetrahydrocannabinol (DELTA9 THC) to be delivered by metered dose inhalers. The formulations, which utilize non-CFC propellants, provide a stable aerosol-deliverable source of DELTA9 THC for the treatment of various medical conditions, such as: nausea and vomiting associated with chemotherapy; muscle spasticity; pain; anorexia associated with AIDS wasting syndrome; epilepsy; glaucoma; bronchial asthma; and mood disorders.
Owner:VIRGINIA COMMONWEALTH UNIV

Carbostyril derivatives and mood stabilizers for treating mood disorders

The pharmaceutical composition of the present invention comprises a carbostyril derivative which is a dopamine-sero-tonin system stabilizer and a mood stabilizer in a pharmaceutically acceptable carrier. The carbostyril derivative may be aripiprazole or a metabolite thereof. The mood stabilizer may include but is not limited to lithium, valproic acid, divalproex sodium, carbamaza-pine, oxcarbamazapine, zonisamide, lamotragine, topiramate, gabapentin, levetiracetam or clonazepam. These compositions are used to treat patients with mood disorders, particularly bipolar disorder with or without psychotic features, mania or mixed episodes. Methods are provided for separate administration of a carbostyril derivative and a mood stabilizer to a patient with a mood disorder.
Owner:OTSUKA PHARM CO LTD

Methods and compositions for treating distress dysfunction and enhancing safety and efficacy of specific medications

The present invention relates to methods and compositions for reducing Distress Dysfunction by restoring and maintaining homeostatic balance in the neurotransmitter systems underlying the Stress Response and the experience of distress and hedonic tone. Distress Dysfunction refers to the experience of dysfunctional emotional and physical distress that interferes with the individual's quality of life and functioning. A novel understanding of the bimodal opioid modulation of pain, and its impact, through serotonergic, dopaminergic, epinephrinergic, and norepinephrinergic processes, on hedonic tone, leads directly to new generation pharmaceutical formulations that are remarkably safe and effective for the treatment of a wide variety of Distress Dysfunctions, including anxiety, depression, anger, insomnia, mood disorders, eating disorders, sexual problems, pain, substance and behavioral addictions, gastrointestinal disorders, autistic spectrum disorders, attention-deficit and hyperactivity disorders, and other emotional and physical distress disorders. The foundation of this discovery is the power of Receptor Switchers, such as ultra-low-dose and very-low-dose opioid antagonists and GM1 ganglioside attenuators, in blocking acute and protracted excitatory opioid receptor signaling. Co-administration of Receptor Switchers with Endorphin Enhancers, such as specific cAMP PDE inhibitors and excitatory amino acids, is an excellent formulation for restoring healthy homeostatic balance to the endogenous opioid system, using the body's endorphins to reduce emotional and physical distress, and through synergistic and homeostatic processes, restoring positive hedonic tone. The addition of Synergistic Enhancers, such as amino acids, SSRI and SNRI agents, and non-opioid analgesics, as well as Exogenous Opioids, enhances and prolongs these therapeutic benefits. The novel principles discovered by this invention also teach a new generation of safe and effective formulations for the treatment of respiratory conditions, neuropathy, and nociceptive pain.
Owner:PONDERA BIOTECH

Method of treating mood disorders and/or anxiety disorders by brain stimulation

ActiveUS20060064138A1Alleviation and modulation of moodAlleviation and modulation of and anxiety disorderElectrotherapyDiagnostic recording/measuringElectrical stimulationsInfusion pump
The present invention involves a method and a system for using electrical stimulation and / or chemical stimulation to treat depression. More particularly, the method comprises surgically implanting an electrical stimulation lead and / or catheter that is in communication with a predetermined site which is coupled to a signal generator and / or infusion pump that release either an electrical signal and / or a pharmaceutical resulting in stimulation of the predetermined site thereby treating the mood and / or anxiety disorder.
Owner:ADVANCED NEUROMODULATION SYST INC

Compositions and methods for diagnosing and treating neuropsychiatric disorders

The present invention provides methods for diagnosing mental disorders (e.g., psychotic disorders such as schizophrenia and mood disorders such as major depression disorder and bipolar disorder). The invention also provides methods of identifying modulators of such mental disorders as well as methods of using these modulators to treat patients suffering from such mental disorders.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV

Combinations of GABA modulators and anticonvulsants, and atypical antipsychotics

This invention relates to combinations of an atypical antipsychotic, and a GABA modulator, a benzodiazepine, and / or an anticonvulsant drug, kits containing such combinations, pharmaceutical compositions comprising such combinations, and methods of using such combinations to treat patients suffering from treatment-resistant anxiety disorders, psychotic disorders or conditions, or mood disorders or conditions.
Owner:PFIZER INC

Method for treating anxiety and mood disorders in older subjects

The present invention is a method for treating anxiety or mood disorders in elderly subjects comprising administering to the subject exhibiting an anxiety or mood disorder an effective amount of an agent that modulates Aβ in the subject.
Owner:ELI LILLY & PATENT DIV

Methods and Compositions for Treating Mood Disorder

The invention relates to compositions and methods for treating mood spectrum disorder. The compositions relate to novel combinations and formulations of pharmaceutical compounds for treatment of mood spectrum disorders. The methods provide for use of the compounds provided herein for the treatment of mood spectrum disorders in addition to the use of mood screens for diagnosing a patient.
Owner:MOOD MANAGEMENT SCI

Magnesium compositions and uses thereof

ActiveUS20080248100A1Increase in physiological concentrationImprove depressionPowder deliveryBiocideAttention deficitsMigraine
A composition for administration to a subject, such as oral administration to a subject, for example, has been provided. Such a composition may comprise at least one magnesium-counter ion compound. A magnesium-counter ion composition described herein may be useful for any of a variety of applications provided herein, such as maintaining, enhancing, and / or improving health, nutrition, and / or another condition of a subject, and / or cognitive, learning, and / or memory function. A magnesium-counter ion composition provided herein may be useful for administration to a subject presenting magnesium deficiency, mild cognitive impairment, Alzheimer's disease, attention deficit hyperactivity disorder, ALS, Parkinson's disease, diabetes, migraine, anxiety disorder, mood disorder, and / or hypertension. A kit, method, and other associated technology are also provided.
Owner:NEUROCENTRIA INC

Substituted 1H-pyrrolo[3,2-b, 3,2-c, and 2,3-c]pyridine-2-carboxamides and related analogs as inhibitors of casein kinase lepsilon

The present invention discloses and claims compounds of formula (I) as inhibitors of human casein kinase IF, and methods of using said compounds of formula (I) for treating central nervous system diseases and disorders including mood disorders and sleep disorders. Pharmaceutical compositions comprising compounds of formula (I) and methods for the preparation of compounds of formula (I) are also disclosed and claimed.
Owner:AVENTISUB LLC

Selective neurostimulation for treating mood disorders

ActiveUS7532935B2Relieve symptomsAlter modulation of neuronal activityHead electrodesDiseaseRegimen
A method and device for treating a mood and / or anxiety disorder are disclosed which comprise electrical, chemical or magnetic stimulation of certain areas of the brain to modulate neuronal activity of areas associated with symptoms of mood disorders. In certain embodiments, deep brain stimulation is combined with cranial nerve stimulation to enhance symptomatic relief of the disorder. Certain embodiments also employ a sensing capability to optimize the therapeutic treatment regimen.
Owner:LIVANOVA USA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products